AIP Stock Analysis: Arteris | NASDAQ
Semiconductors | NASDAQ, USA | Market Cap: 2.281m USD | 12M Return: 277.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 42.5M
Qual. Beats: -1
Rev. Trend: 94.6%
Qual. Beats: 3
Warnings
Tailwinds
Seasonality 4.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Arteris, Inc. (NASDAQ: AIP) is a Campbell, California-based semiconductor IP company founded in 2003 that provides Network-on-Chip (NoC) and related on-chip communication solutions used in System-on-Chip (SoC) semiconductors and chiplet-based systems. Its product portfolio includes flagship NoC IP families such as FlexNoC, FlexGen, FlexWay, Ncore, and CodaCache, alongside hardware security verification tools from its Cycuity Radix line and SoC integration automation software (Magillem Connectivity and Registers, CSRCompiler). The company complements these offerings with professional services, licensing, training, and on-site support, serving clients across the automotive, communications, enterprise computing, consumer electronics, and industrial end markets worldwide.
Arteris operates in the semiconductor intellectual property segment of the broader Information Technology sector, a licensing-driven business model in which customers-typically chip designers and fabless semiconductor firms-pay royalties and licensing fees to integrate Arteris pre-verified connectivity IP into their own chip designs, rather than developing this complex interconnect infrastructure in-house. The companys 2021 IPO on NASDAQ reflects the growing industry demand for reusable, third-party IP as SoC complexity rises, particularly with the industrys shift toward chiplet architectures that require sophisticated on-die and inter-chiplet communication fabrics.
- China revenue exposure to export controls and geopolitical tensions
- Automotive ADAS chip complexity drives NoC IP design wins
- Competition from Synopsys and Cadence pressures licensing market share
| Net Income: -34.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.03 > 0.02 and ΔFCF/TA -4.73 > 1.0 |
| NWC/Revenue: -29.86% < 20% (prev 1.41%; Δ -31.27% < -1%) |
| CFO/TA -0.02 > 3% & CFO -3.19m > Net Income -34.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 0.73 > 1.5 & < 3 |
| Outstanding Shares: last quarter (45.5m) vs 12m ago 11.48% < -2% |
| Gross Margin: 87.96% > 18% (prev 90.18%; Δ -2.22% > 0.5%) |
| Asset Turnover: 64.64% > 50% (prev 62.36%; Δ 2.28% > 0%) |
| Interest Coverage Ratio: -197.3 > 6 (EBIT TTM -36.1m / Interest Expense TTM 183k) |
| A: -0.16 (Total Current Assets 61.5m - Total Current Liabilities 84.5m) / Total Assets 139.9m |
| B: -1.28 (Retained Earnings -179.6m / Total Assets 139.9m) |
| C: -0.30 (EBIT TTM -36.1m / Avg Total Assets 119.1m) |
| D: 0.02 (Book Value of Equity 2.59m / Total Liabilities 137.3m) |
| Altman-Z'' = -7.28 = D |
| DSRI: 1.14 (Receivables 14.7m/10.3m, Revenue 77.0m/61.3m) |
| GMI: 1.03 (GM 90.18% / 87.96%) |
| AQI: 1.48 (AQ_t 0.50 / AQ_t-1 0.34) |
| SGI: 1.26 (Revenue 77.0m / 61.3m) |
| TATA: -0.22 (NI -34.6m - CFO -3.19m) / TA 139.9m) |
| Beneish M = -2.45 (Cap -4..+1) = BBB |
As of July 06, 2026, the stock is trading at USD 35.06 with a total of 1,759,353 shares traded. Over the past week, the price has changed by -19.57%, over one month by +2.28%, over three months by +92.21% and over the past year by +277.40%.
Current recommended Stop Loss: 31.30 (which is 10.7% or 1.2 ATR below the current price).
Arteris has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy AIP.
- StrongBuy: 3
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 37.8 | 7.7% |
P/S = 29.6346
P/B = 843.9618
Revenue TTM = 77.0m USD
EBIT TTM = -36.1m USD
EBITDA TTM = -32.2m USD
Long Term Debt = 452k USD (from longTermDebt, last quarter)
Short Term Debt = 1.37m USD (from shortTermDebt, last quarter)
Debt = 5.46m USD (from shortLongTermDebtTotal, last quarter) (leases 5.46m already included)
Net Debt = -32.6m USD (calculated: Debt 5.46m - CCE 38.1m)
Enterprise Value = 2.25b USD (2.28b + Debt 5.46m - CCE 38.1m)
Interest Coverage Ratio = -197.3 (Ebit TTM -36.1m / Interest Expense TTM 183k)
EV/FCF = -479.6x (Enterprise Value 2.25b / FCF TTM -4.69m)
FCF Yield = -0.21% (FCF TTM -4.69m / Enterprise Value 2.25b)
FCF Margin = -6.09% (FCF TTM -4.69m / Revenue TTM 77.0m)
Net Margin = -44.92% (Net Income TTM -34.6m / Revenue TTM 77.0m)
Gross Margin = 87.96% ((Revenue TTM 77.0m - Cost of Revenue TTM 9.27m) / Revenue TTM)
Gross Margin QoQ = 83.01% (prev 90.76%)
Tobins Q-Ratio = 16.08 (Enterprise Value 2.25b / Total Assets 139.9m)
Interest Expense / Debt = 3.35% (Interest Expense 183k / Debt 5.46m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -28.5m (EBIT -36.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.73 (Total Current Assets 61.5m / Total Current Liabilities 84.5m)
Debt / Equity = 2.11 (Debt 5.46m / totalStockholderEquity, last quarter 2.59m)
Debt / EBITDA = 1.01 (negative EBITDA) (Net Debt -32.6m / EBITDA -32.2m)
Debt / FCF = 6.96 (negative FCF - burning cash) (Net Debt -32.6m / FCF TTM -4.69m)
Total Stockholder Equity = -7.75m (last 4 quarters mean from totalStockholderEquity)
RoA = -29.04% (Net Income -34.6m / Total Assets 139.9m)
RoE = 446.0% (negative equity) (Net Income TTM -34.6m / Total Stockholder Equity -7.75m)
RoCE = 494.5% (negative capital employed) (EBIT -36.1m / Capital Employed (Equity -7.75m + L.T.Debt 452k))
RoIC = -53.95% (negative operating profit) (NOPAT -28.5m / Invested Capital 52.9m)
WACC = 15.25% (E(2.28b)/V(2.29b) * Re(15.28%) + D(5.46m)/V(2.29b) * Rd(3.35%) * (1-Tc(0.21)))
Discount Rate = 15.28% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 100.00 | Cagr: 11.23%
[DCF] Fair Price = unknown (Cash Flow -4.69m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -4.0 | # QB: -1
Revenue Correlation: 94.63 | Revenue CAGR: 14.73% | SUE: 3.56 | # QB: 3
EPS current Quarter (2026-06-30): EPS=-0.04 | Chg30d=N/A | Revisions=+40% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.02 | Chg30d=N/A | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=-0.09 | Chg30d=N/A | Revisions=+40% | GrowthEPS=+73.5% | GrowthRev=+33.2%
EPS next Year (2027-12-31): EPS=0.16 | Chg30d=N/A | Revisions=+25% | GrowthEPS=+282.9% | GrowthRev=+20.3%
[Analyst] Revisions Ratio: +50% (up=6, down=1)